TY - JOUR
T1 - Treatment of diabetic foot infection
T2 - An open randomised comparison of imipenem/cilastatin and piperacillin/clindamycin combination therapy
AU - Bouter, K. Paul
AU - Visseren, Frank L.J.
AU - Van Loenhout, Ruud M.M.
AU - Bartelink, Anton K.M.
AU - Erkelens, D. Willem
AU - Diepersloot, Rob J.A.
PY - 1996/1/1
Y1 - 1996/1/1
N2 - Objective: To compare the clinical outcome and bacteriological response in diabetic patients with a foot infection treated with imipenem/cilastatin or a combination of piperacillin/clindamycin. Methods: Patients hospitalised for diabetic foot lesions Wagner Stages II, III or IV were randomly assigned to receive either imipenem/cilastatin 500 mg QID or piperacillin 3000 mg QID in combination with clindamycin 600 mg TID. Cultures were obtained and clinical observations were made. Results: Forty-six patients (mean age 71.4 ± 9.8 years) entered the study, 22 received imipenem/cilastatin (IC) and 24 received piperacillin/clindamycin (PCL) combination therapy. In the IC group 22.2% was considered to be clinically cured, 76.2% improved. In the PCL group this was 25.0% and 50.0%, respectively. In the IC treatment group 45.0% of baseline pathogens was eradicated compared to 70.0% in the PCL group. Adverse events were more often reported in PCL treated patients (50.0% vs. 19.0% P < 0.05). Conclusions: Imipenem/cilastatin and piperacillin/clindamycin combination therapy were equally effective in the treatment of patients with diabetic foot lesions. The imipenem/cilastatin regimen caused less side effects.
AB - Objective: To compare the clinical outcome and bacteriological response in diabetic patients with a foot infection treated with imipenem/cilastatin or a combination of piperacillin/clindamycin. Methods: Patients hospitalised for diabetic foot lesions Wagner Stages II, III or IV were randomly assigned to receive either imipenem/cilastatin 500 mg QID or piperacillin 3000 mg QID in combination with clindamycin 600 mg TID. Cultures were obtained and clinical observations were made. Results: Forty-six patients (mean age 71.4 ± 9.8 years) entered the study, 22 received imipenem/cilastatin (IC) and 24 received piperacillin/clindamycin (PCL) combination therapy. In the IC group 22.2% was considered to be clinically cured, 76.2% improved. In the PCL group this was 25.0% and 50.0%, respectively. In the IC treatment group 45.0% of baseline pathogens was eradicated compared to 70.0% in the PCL group. Adverse events were more often reported in PCL treated patients (50.0% vs. 19.0% P < 0.05). Conclusions: Imipenem/cilastatin and piperacillin/clindamycin combination therapy were equally effective in the treatment of patients with diabetic foot lesions. The imipenem/cilastatin regimen caused less side effects.
KW - Antibiotic therapy
KW - Clinical trial
KW - Diabetic foot
UR - http://www.scopus.com/inward/record.url?scp=0030199354&partnerID=8YFLogxK
U2 - 10.1016/0924-8579(96)00305-6
DO - 10.1016/0924-8579(96)00305-6
M3 - Article
AN - SCOPUS:0030199354
SN - 0924-8579
VL - 7
SP - 143
EP - 147
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 2
ER -